Kruszka - Sjogren_Final2


Published on

  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • Early signs of dry mouth due to Sjogren’s syndrome can include diminution of the sublingual salivary pool, cheilosis and loss of glistening of the tongue and mucous membranes. A tongue depressor may readily adhere to the sticky mucosal surfaces, as will undigested food particles. The patient may be unable to lick a standard letter envelope completely sealed. In advanced disease (pictured above), the tongue and mucosal surface become erythematous, fissured or ulcerated, and the sublingual salivary pool disappears.
  • Dry mouth due to advanced Sjogren’s syndrome may lead to rampant dental caries (usually at the necks and incisal surfaces of teeth) and, in some cases, eventual loss of dentition. Other complications may include oral ulcers and candidiasis. In one study, periodontal disease was 2.2 times more likely to develop in Sjogren’s syndrome patients than healthy controls. Dentists can therefore play a vital role in early diagnosis and proper management.
  • The Schirmer test (minus anesthesia) measures reflex tear secretion “ Schirmer I” With anesthesia (“Schirmer II”), eliminates stimulated tearing Stimulated tearing can occur because of introduction of the filter paper strip Measures so-called “basal” tearing A filter paper strip is introduced to the lower lid of the eye Dry eye is indicated if less than 10 mm of the strip becomes wet with tears after 5 minutes of exposure Lemp. CLAO J. 1995;21:221-232.
  • Kruszka - Sjogren_Final2

    1. 1. Diagnosis and Management of Sjogren’s Syndrome LCDR Paul Kruszka, USPHS/USCG [email_address]
    2. 2. What is Sjogren’s Syndrome <ul><li>Systemic autoimmune disease characterized by dry eyes and dry mouth. </li></ul><ul><li>Other organ systems often affected (extra-glandular manifestations) </li></ul><ul><li>May be primary - solitary process </li></ul><ul><li>Secondary disease accompanies another autoimmune disease - most often rheumatoid arthritis or SLE </li></ul>
    3. 3. Glossary <ul><li>Xerostomia </li></ul><ul><li>Xerophthalmia </li></ul><ul><li>Keratoconjunctivitis sicca : KCS </li></ul><ul><li>Sialadenitis </li></ul>
    4. 4. Epidemiology <ul><li>Sjogren Syndrome is the third most common autoimmune disease </li></ul><ul><li>The reported prevalence is between 0.05 and 4.8% 1 </li></ul><ul><li>A study from Olmsted, MN found physician diagnosed cases to be approximately 4 per 100,000 persons. 1 </li></ul><ul><li>1. Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsed County, Minnesota. Mayo Clin Proc. 2001;76(6):593-599. </li></ul>
    5. 5. Who gets Sjogren Syndrome <ul><li>A cohort of 400 patients found that the average age of the patients was 52.7 and 93% of the patients were women. 2 </li></ul><ul><li>An estimated 1 to 2 million Americans have Sjogren Syndrome. 1 </li></ul><ul><li>Primary vs. secondary </li></ul><ul><li>2. Garcia-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine. 2002;81(4):270-280. </li></ul>
    6. 6. Pathogenesis <ul><li>Obscure </li></ul><ul><li>Primary Sjogren syndrome is associated with HLA-DR3; RR = 10 3 </li></ul><ul><li>The histologic hallmark: lymphocytic infiltration of exocrine glands leading to gland degeneration, necrosis, and atrophy 4 </li></ul><ul><li>Evidence of B cell role: auto-antibodies to self antigens </li></ul><ul><li>Mitchell RS, Kumar V, Abbas AK, Fausto N. Robbins Basic Pathology 8th edition. Philadelphia 2007. </li></ul><ul><li>4. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of Primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003;49(4):585-593. </li></ul>
    7. 7. Normal Minor Salivary Gland
    8. 8. Minor Salivary Gland Bx
    9. 9. Lip biopsy
    10. 10. Presentation <ul><li>In a prospective cohort study of 400 patients, 98% presented with dry mouth and 93% presented with dry eyes. 2 </li></ul><ul><li>Associated dry mouth symptoms: difficulty speaking and eating and swallowing, and frequents sips of water. 5 </li></ul><ul><li>Associated dry eye symptoms: grittiness, dryness, pruritis, foreign body sensation. </li></ul><ul><li>In one study of 195 Dutch patients, 85% reported fatigue 12 </li></ul><ul><li>5. Kruszka PS and O’Brian RJ. Diagnosis and Management of Sjogren Syndrome. Am Fam Physician. 2009;79(6):465-470. </li></ul>
    11. 11. Extraglandular Manifestations 5 6 Fever not associated with infectious process 6 Renal involvement (proteinuria, renal tubular acidosis, interstitial nephritis, glomerulonephritis, abnormal urinalysis) 7 Lymphadenopathy (cervical, axillary, or inguinal) 7 Peripheral neuropathy 12 Cutaneous vasculitis 16 to 28 Raynaud’s phenomenon 29 Pulmonary disease (chronic cough, recurrent bronchitis with diffuse interstitial infiltrates on radiography, abnormal spirometry, pulmonary alveolitis or fibrosis on computed tomography) 15 to 33 Autoimmune thyroiditis 54 Gastrointestinal symptoms 37 to 75 Arthralgia/non-erosive arthritis characterized by tenderness, swelling, or effusion of peripheral joints frequency Clinical signs/symptoms
    12. 12. Physical Exam Findings <ul><li>Conjunctival injection </li></ul><ul><li>Corneal clouding </li></ul><ul><li>Decreased salivary pool and dry mucous membranes </li></ul><ul><li>Dental caries </li></ul><ul><li>Parotid gland enlargement and tenderness </li></ul>
    13. 13. Sjogren’s Syndrome Oral Signs Slide reprinted from the Clinical Slide Collection on the
    14. 14. Sjogren’s Syndrome Dental Caries Due to Untreated Dry Mouth
    15. 15. Diagnosis <ul><li>Diagnosis of primary Sjogren Syndrome is strongly suggested in a patient with: </li></ul><ul><ul><li>Signs and symptoms of oral ocular dryness </li></ul></ul><ul><ul><li>Positive antibodies for anti-SS-A and anti-SS-B antigen OR positive salivary gland biopsy </li></ul></ul><ul><li>Sjogren syndrome often has an insidious onset, a variable course, and a wide spectrum of clinical manifestations, making diagnosis difficult and delayed. </li></ul>
    16. 16. Frequency of Positive Laboratory Test Results in Primary Sjogren Syndrome 32 to 90 Rheumatoid factor 7 to 50 Anti-SSB (La) 16 to 70 Anti-SSA (Ro) 55 to 97 Antinuclear antibody Frequency (%) Tests
    17. 17. Revised International Classification Criteria for Sjogren Syndrome <ul><li>Criteria established for homogeneity of research cohorts </li></ul><ul><li>Provide a useful framework to make a diagnosis </li></ul><ul><li>The classification requires four of the six items, one of which must be a positive minor salivary gland biopsy or a positive antibody test, or the presence of three of the four objective items </li></ul>
    18. 18. <ul><li>Revised International Classification Criteria for Sjogren Syndrome </li></ul><ul><li>Ocular symptoms (at least one of the following): daily, persistent, troublesome dry eyes for more than 3 months, recurrent sensation of sand or gravel in eyes, use of tear substitutes more than three time per day </li></ul><ul><li>Oral symptoms (at least one of the following symptoms): daily feeling of dry mouth for more than three months, recurrent or persistently swollen salivary glands as a adult, need to drink liquids frequently to aid in swallowing dry food. </li></ul><ul><li>Ocular signs (at least one positive): Schirmer test, Rose Bengal test or other ocular dye test </li></ul><ul><li>Histopathology (positive biopsy of a salivary gland) </li></ul><ul><li>Salivary gland involvement (positive results from at least one of the following tests): unstimulated whole salivary flow collection (less than 1.5ml in 15 minutes); parotid sialography showing the presence of diffuse sialectasia; Salivary scintigraphy showing delayed uptake, reduced concentration and delayed excretion of tracer </li></ul><ul><li>Presence of Anti-SSA and Anti-SSB </li></ul>
    19. 19. Schirmer Test <ul><li>Without anesthesia </li></ul><ul><li>Measures reflex tear secretion </li></ul><ul><li>With anesthesia </li></ul><ul><li>Eliminates stimulated tearing </li></ul>Permission to use slide granted from Sjogren’s Syndrome Foundation
    20. 20. Non-stimulated whole saliva flow <ul><li>Spit into graduated test tube every minute for 15 minutes. </li></ul><ul><li>Collection of less than 1.5mL in 15 minutes is considered positive </li></ul>
    21. 21. Differential diagnosis for dry eyes Burning, eyelid swelling/erythema Rosacea Diuretics and anticholinergics. Medications for: Alzheimer's, Parkinson's, allergic rhinitis, depression, incontinence Medications Diminished blinking during long periods of driving, reading, computer Lifestyle Wind, dust, low humidity, irritants Environment Eyelid erythema and crusting, worse in morning, does not respond to eye drops Blepharitis Burning eyes, conjunctival injection, and mucoid secretion Allergic conjunctivitis Comment Condition
    22. 22. Differential diagnosis for xerostomia Non-caseating granulomas in salivary glands Sarcoidosis Mouth breathing Obstructed nasal passages Diuretics and anticholinergics Medications HIV medication Sialadenitis results in 15% of patients with Hep C Hepatitis C External beam radiation damages salivary glands Head and neck radiation Dryness worsens with poor gylcemic control Diabetes Comment Condition
    23. 23. Treatment <ul><li>No known cure </li></ul><ul><li>Treatment focuses on relieving symptoms and preventing complications </li></ul><ul><li>Treatment can be grouped into regimens for </li></ul><ul><ul><li>General measures </li></ul></ul><ul><ul><li>KCS </li></ul></ul><ul><ul><li>Xerostomia </li></ul></ul><ul><ul><li>Systemic manifestations </li></ul></ul>
    24. 24. General Measures <ul><li>Avoidance of drugs that worsen sicca symptoms </li></ul><ul><li>Avoidance of low humidity environments </li></ul><ul><li>Use of humidifiers </li></ul><ul><li>Avoid dust and cigarette smoke </li></ul><ul><li>Good oral hygiene </li></ul>
    25. 25. Keratoconjunctivitis sicca: Goals of Treatment <ul><li>Symptom relief </li></ul><ul><li>Prevention of keratitis, corneal ulceration, scarring of the ocular surface </li></ul>
    26. 26. Keratoconjunctivitis sicca <ul><li>Topical tear replacement </li></ul><ul><li>Increasing tear production with stimulation of muscarinic receptors </li></ul><ul><li>Anti-inflammatory medications </li></ul><ul><li>Punctal occlusion </li></ul><ul><li> </li></ul>
    27. 27. OTC eye drops <ul><li>Resources </li></ul><ul><ul><li>FDA Consumer Magazine </li></ul></ul><ul><ul><li> </li></ul></ul><ul><ul><li>Sjogren Foundation </li></ul></ul><ul><ul><li> </li></ul></ul>
    28. 28. Preservative free eye drops
    29. 29. Muscarinic agonists (SORT B) <ul><li>Oral pilocarine (Salagen) at a dosage of 5mg twice daily has been shown in a small RCT to decrease subjective eye symptoms and improve results of rose Bengal testing </li></ul><ul><li>Oral cevimeline (Evoxac) at a dosage of 30mg three times daily relieved subjective eye symptoms in another small RCT. </li></ul><ul><li>Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren’s syndrome: a randomized 12 week controlled study. Ann Rheum Dis. 2003;62(12):1204-1207. </li></ul><ul><li>Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138(1):6-17. </li></ul>
    30. 30. SORT <ul><li>A = consistent, good-quality patient-oriented evidence </li></ul><ul><li>B = inconsistent or limited-quality patient-oriented evidence </li></ul><ul><li>C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series </li></ul>
    31. 31. Muscarinic side effects <ul><li>Sweating </li></ul><ul><li>Abdominal pain </li></ul><ul><li>Flushing </li></ul><ul><li>Increased urination </li></ul>
    32. 32. Muscarinic contraindications <ul><li>Asthma </li></ul><ul><li>Angle closure glaucoma </li></ul>
    33. 33. Topical cyclosporine (Restasis) <ul><li>Symptoms of dryness improved (n=15) </li></ul><ul><li>No change in Schirmer test </li></ul><ul><li>Jain AK, Sukhija J, Dwedi s, Sood A. Effect of topical cyclosporine on tear functions in tear-deficient dry eyes. Ann Ophthalmol. 2007:39(1):19-25 (Abstract). </li></ul>
    34. 34. Punctal Plugs <ul><li>Temporary or permanent silicone </li></ul><ul><li>Improves rose bengal staining scores </li></ul><ul><li>No change in Schirmer values </li></ul><ul><li>Sakamoto A, Kitagawa K, Tatami A. Efficacy and retention rate of two types of silicone punctal plugs in patients with and without sjogren syndrome. Corea. 2004 Apr;23(3):249-54. </li></ul>
    35. 35. Goals of treatment: Xerostomia <ul><li>Alleviate symptoms </li></ul><ul><li>Prevent complications </li></ul><ul><ul><li>Dental caries </li></ul></ul><ul><ul><li>Gum disease </li></ul></ul><ul><ul><li>Halitosis </li></ul></ul><ul><ul><li>Salivary gland calculi </li></ul></ul><ul><ul><li>dysphagia </li></ul></ul>
    36. 36. Xerostomia <ul><li>Good oral hygiene </li></ul><ul><li>Salivary stimulation </li></ul><ul><li>Saliva substitutes </li></ul><ul><li>Recognition of complications </li></ul><ul><li>Daily topical fluoride and antimicrobial mouth rinses 8 </li></ul><ul><li>Sugar free chewing gum (Xylitol) 9 </li></ul><ul><li>Salivary substitutes </li></ul><ul><li>Ship JA. Diagnosing, managing, and preventing salivary gland disorders. Oral Dis. 2002;8(2):77-89. </li></ul><ul><li>Burt BA. The use of sorbitol and xylitol-sweetened chewing gum in caries control. J Am Dent Assoc. 2006;137(2):190-196. </li></ul>
    37. 37. Artificial saliva
    38. 38. Muscarinic agonists in xerostomia <ul><li>Pilocarpine: a small RCT of 44 patients showed 5mg four times daily improved subjective xerostomia. 10 </li></ul><ul><li>Cevimeline: 30mg three times daily improved symptoms and salivary flow. 11 </li></ul><ul><li>Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjogren’s Syndrome in Taiwan-a double-blind, placebo-controlled trial. J Formos Med Assoc. 2006;105(10):796-803. </li></ul><ul><li>Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patient’s with Sjogren syndrome: a randomized trial. Arch Intern Med. 2002;162(11):1293-1300. </li></ul>
    39. 39. Interferon alpha <ul><li>Improvement in subjective oral and ocular dryness and an increase in non-stimulated whole saliva flow. 13 </li></ul><ul><li>A smaller study showed improvement in histologically normal-appearing minor salivary gland lip biopsies. 14 </li></ul><ul><li>Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003; 49(4):585-593. </li></ul><ul><li>14. Shiozawa S,, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sogren’s syndrome. J Interferon Cytokine Res. 199818(4):255-262. </li></ul>
    40. 40. Anti-Tumor Necrosis Factor (anti-TNF) <ul><li>Varied results </li></ul><ul><li>Largest RCT of 103 patients treated with Remicade </li></ul><ul><ul><li>Evaluated at 10 and 22 weeks </li></ul></ul><ul><ul><li>No change in subjective oral/ocular dryness </li></ul></ul><ul><ul><li>No objective improvement: Schirmer’s test or focus score on labial salivary gland biopsy </li></ul></ul><ul><ul><li>Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sogren syndrome: results of the randomized controlled Trial of Remicade in Primary Sjogrens Syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270-1276. </li></ul></ul>
    41. 41. Rituximab <ul><li>Chimeric monoclonal antibody </li></ul><ul><li>Targets B lymphocyte antigen CD20 </li></ul><ul><li>Case reports and pilot studies show successful treatment of SS with Rituximab </li></ul><ul><li>Alcantara C, Gomes MJ, Ferreira C. Rituximab Therapy in Primary sogren’s syndrome. Ann. NY Acad. Sci. 2009;1173:701-5. </li></ul>
    42. 42. Rituximab Treatment <ul><li>Open label study of 16 patients </li></ul><ul><li>36 week follow-up </li></ul><ul><li>Subjective improvements in disease activity and quality of life. </li></ul><ul><li>Depletion of B cells in blood and salivary gland biopsy </li></ul><ul><li>Devauchelle-Pensec V, Pennec Y, Morvan J, Pers J, Daridon Cousse-Joulin S. Improvement of Sjogren’s Syndrome After Two Infusions of Rituximab. Arth. Rheum. 2007;57(2):310-317 </li></ul>
    43. 43. Rituximab RCT <ul><li>Double blind RCT </li></ul><ul><li>17 patients </li></ul><ul><li>Significant improvement in fatigue VAS (p<0.001) </li></ul><ul><li>Dass S, Bowman s, Vital EM et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind placebo controlled pilot study. Ann. Rheum. Dis. 2008;67:1541-1544. </li></ul>
    44. 44. Treatment survey of 195 Dutch patients 12. Meijer JM, Meiners PM, Huddleston JR, Spijkervet FK, Kallenberg CG, Vissink A et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheum 2009;48:1077-1082. 18(9) Anti-depressants 17(9) Other immunosuppressives 20(10) Rituximab 26(13) Oral corticosteroids 31(16) Anti-malarial drugs 47(24) NSAIDs 18(9) Pilocarpine 20(10) Artificial saliva 46(24) Oral moisturizing gel 151(77) Artificial tears n=195(%) Therapy
    45. 45. Prognosis <ul><li>In comparison to the general Dutch population, 47% vs. 1.5% received disability compensation (p<0.001) 12 </li></ul><ul><li>Increased risk of non-Hodgkins lymphoma (NHL) </li></ul>
    46. 46. NHL <ul><li>16-fold increased risk compared to general population </li></ul><ul><li>Prospective study of 508 Swedish patients </li></ul><ul><li>Significant predictors: </li></ul><ul><ul><li>Purpura/skin vasculitis (HR 4.64(1.13-16.45)) </li></ul></ul><ul><ul><li>Low C3 (HR 6.18(1.57-24.22)) </li></ul></ul><ul><ul><li>Low C4 (HR 9.49(1.94-46.54)) </li></ul></ul><ul><ul><li>CD4+ lymphocytopenia (HR 8.14, 2.10-31.53)) </li></ul></ul><ul><ul><li>Low CD4+/CD8+ ratio < 0.8 (HR 10.92,2.80-41.83)) </li></ul></ul><ul><ul><li>Theander E, Henriksson G, Ljungber O, Mandl T, Manthorpe R, Jacobs LT. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796-803. </li></ul></ul>
    47. 47. Future direction <ul><li>Anti-CD22 (Epratuxumab) </li></ul><ul><li>Anti-BAFF (B cell-activating factor) </li></ul><ul><li>Meijer JM, Pipe J, Bootsma H, Vissink A, Kallenber CG. The Future of Biologic Agents in the Treatment of Sjogren’s Syndrome. Clinic Rev Allerg Immunol 2007;32:292-297. </li></ul>
    48. 48. Summary <ul><li>Chronic dry eyes and dry mouth - consider Sjogren’s Syndrome </li></ul><ul><li>Muscarinic agonists improve subjective and objective signs and symptoms of xerostomia (SORT B) </li></ul><ul><li>Interferon alpha improves subjective oral and ocular dryness and increases nonstimulated saliva flow in patiens with Sjogren’s syndrome (SORT B) </li></ul>